Physician profile
Renee Hall
NPI 1316671217
$1,873.56
in general payments reported to CMS, 2019-2025
18 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $523 · 2024: $771 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $330.35 | 2023-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $261.04 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $222.69 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $188.56 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Corium, LLC | $126.42 | 2024-2025 | Azstarys |
| Abbvie INC. | $123.50 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $123.23 | 2025 | Fanapt |
| Lundbeck LLC | $103.11 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $81.65 | 2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.61 | 2023-2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $44.50 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $42.24 | 2024 | Secuado, Xelstrym |
| Janssen Pharmaceuticals, INC | $32.83 | 2023-2024 | Invega Sustenna, Spravato |
| Baxter Healthcare | $32.14 | 2025 | Coseal, Tisseel, Surgical Tools |
| Jazz Pharmaceuticals INC. | $31.16 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.85 | 2025 | Rejoyn |
| Acadia Pharmaceuticals INC | $18.29 | 2023 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $15.39 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.